PMC5131445_01
The photographs the patient before treatment pazopanib
13569_2016_61_Fig1_HTML.jpg
PMC5131445_01_13569_2016_61_Fig1_HTML.jpg
Fig1
One month after the initiation of pazopanib, he presented with vitiligo and hair depigmentation (Figs. 1, 2) which are quite common side effects of pazopanib.  
One month after the start of pazopanib treatment; Patient presented with loss of hair color and vitiligo
13569_2016_61_Fig2_HTML.jpg
PMC5131445_01_13569_2016_61_Fig2_HTML.jpg
Fig2
One month after the initiation of pazopanib, he presented with vitiligo and hair depigmentation (Figs. 1, 2) which are quite common side effects of pazopanib.  
Patient CT scans; a before initial treatment of tamoxifen; axial plan CT scan performed in September 2013 demonstrates 2.89 cm diameter homogeneous mass located at the left anterior pararenal space of the retroperitoneal area (yellow arrow). b Post contrast CT images in december 2013; retroperitoneal mass (diameter 4.14 cm) progressed after treatment of tamoxifen (yellow arrow). c 9 months after the initiation of pazopanib treatment; the residual mass regressed on CT scan at same level (yellow arrow). d Post contrast CT images obtained in October 2015 showing complete response of the residual mass at 22 months of pazopanib treatment.(yellow arrow)
13569_2016_61_Fig3_HTML.jpg
PMC5131445_01_13569_2016_61_Fig3_HTML.jpg
Fig3
After 3 months on tamoxifen, progressive disease was detected by CT scan (Fig. 3a, b). On the follow-up period, first response to treatment was documented 4 months after the initiation of treatment (Fig. 3c). The response to treatment lasted on the follow-up visits, and after 22 months on pazopanib; complete response was achieved on patient's last scan (Fig. 3d).